Citicoline Treatment Increases Retinal Dopamine Content in Rabbits

Ręjdak, Robert; Toczołowski, J; Solski, Janusz; Duma, D; Grieb, Paweł

doi:10.1159/000063658

Cited by 56 publications

(50 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, stimulation of the dopaminergic system caused by CDP-choline may be a common mechanism that causes both an improvement in the motor symptoms experienced by patients suffering from Parkinson's disease and an improvement in the retinal and post-retinal performance of glaucomatous patients. In accordance with this theory, it was observed that in rabbits treated with CDP-choline [33] the concentration of dopamine in the retina increased.…”

Section: Introductionsupporting

confidence: 63%

Effect of oral CDP-choline on visual function in young amblyopic patients

Fresina

Dickmann

Salerni

et al. 2007

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

Section: Introductionsupporting

confidence: 63%

Effect of oral CDP-choline on visual function in young amblyopic patients

Fresina

Dickmann

Salerni

et al. 2007

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Conversely, dopaminergic uptake has been associated with improved performance on working memory and executive function tasks requiring attention [25,26]. Previous investigations have shown that citicoline increases dopamine [10,27], increases dopamine receptor densities [28], and aids in protection of neurons related to dopamine [29]. While dopamine was not measured in the current study, it seems likely that dopamine increases identified with citicoline supplementation may explain the improved performance on attention tasks shown in the present study.…”

Section: Discussioncontrasting

confidence: 46%

Improved Attentional Performance Following Citicoline Administration in Healthy Adult Women

McGlade¹,

Locatelli²,

Hardy³

et al. 2012

FNS

View full text Add to dashboard Cite

Objectives: The present study assessed the potential cognitive-enhancing effects of citicoline, a dietary supplement, in healthy adult women. Specifically, it was hypothesized that citicoline supplementation would be associated with improved attention compared to placebo. Methods: The investigation was a double-blind, randomized, placebo-controlled three-arm study. Sixty healthy adult women ages 40 -60 completed a clinical screening visit, including a medical exam. After study enrollment each subject was randomly assigned to one of three groups: a daily oral dose of 250 mg citicoline, 500 mg citicoline, or placebo for 28 days. Participants were evaluated with the Continuous Performance Test II (CPT-II), a measure sensitive to attentional function, during a baseline visit and 28 days after baseline. Results: All 60 participants were included in the analyses, which included an ANOVA with Tukey's post-hoc tests and t-tests. After 28 days of supplementation, individuals in the 250 mg group made fewer omission (p = 0.04) and commission (p = 0.03) errors compared to those in the placebo group. Individuals in the 500 mg group made significantly fewer commission errors compared to those in the placebo group (p = 0.03) and trended toward making fewer omission errors (p = 0.07). Conclusion: After 28 days of daily citicoline supplementation, participants who were administered either the 250 mg or the 500 mg citicoline doses showed significantly better ability to produce correct responses on the CPT-II, likely due to improved cognitive inhibition. Our findings suggest that citicoline may improve attentional performance in middle-aged women and may ameliorate attentional deficits associated with central nervous system disorders.

show abstract

“…A second mechanism that may explain why citicoline improves function in chronically injured animals focuses on observed decreases in dopamine following injury (Yan et al, 2001). In such models, citicoline increased dopamine levels (Ross et al, 2001;Rejdak et al, 2002;Secades and Frontera, 1995), which enhances neurorecovery (Kline et al, 2004).…”

Section: Methodsmentioning

confidence: 99%

The Citicoline Brain Injury Treatment (COBRIT) Trial: Design and Methods

Zafonte

Friedewald

Lee

et al. 2009

Journal of Neurotrauma

View full text Add to dashboard Cite

Traumatic brain injury (TBI) is a major cause of death and disability. In the United States alone approximately 1.4 million sustain a TBI each year, of which 50,000 people die, and over 200,000 are hospitalized. Despite numerous prior clinical trials no standard pharmacotherapy for the treatment of TBI has been established. Citicoline, a naturally occurring endogenous compound, offers the potential of neuroprotection, neurorecovery, and neurofacilitation to enhance recovery after TBI. Citicoline has a favorable side-effect profile in humans and several meta-analyses suggest a benefit of citicoline treatment in stroke and dementia. COBRIT is a randomized, double-blind, placebo-controlled, multi-center trial of the effects of 90 days of citicoline on functional outcome in patients with complicated mild, moderate, and severe TBI. In all, 1292 patients will be recruited over an estimated 32 months from eight clinical sites with random assignment to citicoline (1000 mg twice a day) or placebo (twice a day), administered enterally or orally. Functional outcomes are assessed at 30, 90, and 180 days after the day of randomization. The primary outcome consists of a set of measures that will be analyzed as a composite measure using a global test procedure at 90 days. The measures comprise the following core battery: the California Verbal Learning Test II; the Controlled Oral Word Association Test; Digit Span; Extended Glasgow Outcome Scale; the Processing Speed Index; Stroop Test part 1 and Stroop Test part 2; and Trail Making Test parts A and B. Secondary outcomes include survival, toxicity, and rate of recovery.

show abstract

Citicoline Treatment Increases Retinal Dopamine Content in Rabbits

Cited by 56 publications

References 17 publications

Effect of oral CDP-choline on visual function in young amblyopic patients

Effect of oral CDP-choline on visual function in young amblyopic patients

Improved Attentional Performance Following Citicoline Administration in Healthy Adult Women

The Citicoline Brain Injury Treatment (COBRIT) Trial: Design and Methods

Contact Info

Product

Resources

About